Current state and limitations of daily oral therapy for treatment

被引:31
作者
Solomon, Daniel A. [1 ]
Sax, Paul E. [1 ]
机构
[1] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02130 USA
关键词
antiretroviral; HIV; limitations; oral; strengths; HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; DISEASE RISK; TENOFOVIR; INFLAMMATION; COAGULATION; PREVENTION; INHIBITORS; LAMIVUDINE;
D O I
10.1097/COH.0000000000000165
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewWe aim to review the strengths and weaknesses of current antiretroviral therapy (ART), and describe ongoing research to address limitations to current therapy.Recent findingsCurrent ART is highly effective and well tolerated. As a result of a decrease in medication side-effects and pill burden, and the known health effects of uncontrolled viremia, ART is now recommended at all CD4 cell counts in the USA. Novel medications are being developed to further decrease side-effects and offer alternative options for patients with multiclass resistance. New combination pills will further decrease pill burden.SummaryCurrent treatment for HIV is characterized by highly potent oral antiretroviral medications, which are well tolerated, resulting in outstanding rates of virologic suppression in patients who are adherent to therapy. Despite the marked improvement in therapeutic options, limitations to therapy still exist including reliance on daily adherence, long-term toxicity of medications, drug-drug interactions, long-term effects of HIV even in the setting of viral suppression, high lifetime cost of treatment, and limited options for some patients with multiclass resistance. Emerging alternative treatment strategies include nucleoside reverse transcriptase inhibitor-sparing or limiting regimens and long-acting injectable combination therapy.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 50 条
  • [1] Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
    Angiolillo, Dominick J.
    DIABETES CARE, 2009, 32 (04) : 531 - 540
  • [2] State of the HAART" - Current strategies for antiretroviral therapy
    Staszewski S.
    Stephan C.
    Der Internist, 2004, 45 (12): : 1428 - 1436
  • [3] State of the HAART - Current strategies for antiretroviral therapy
    Staszewski, S
    Stephan, C
    INTERNIST, 2004, 45 (12): : 1428 - 1436
  • [4] Oral antiretroviral chemoprophylaxis: current status
    Baeten, Jared
    Celum, Connie
    CURRENT OPINION IN HIV AND AIDS, 2012, 7 (06) : 514 - 519
  • [5] The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations
    Prandoni, Paolo
    BLOOD TRANSFUSION, 2015, 13 (02) : 178 - 180
  • [6] A Review of Oral Antiretroviral Therapy for the Treatment of Chronic Hepatitis B
    Hynicka, Lauren M.
    Yunker, Nancy
    Patel, Punam H.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (7-8) : 1271 - 1286
  • [7] Expanding Treatment Opportunities: Reviewing the Current State of Injectable Antiretrovirals for Treatment of HIV
    Binkley, Amanda
    Zimmerman, Matty
    Maguire, Christina
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (12) : 2475 - 2488
  • [8] Antiretroviral Therapy Current Drugs
    Pau, Alice K.
    George, Jomy M.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2014, 28 (03) : 371 - +
  • [9] Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States
    Masters, Mary Clare
    Krueger, Karen M.
    Williams, Janna L.
    Morrison, Lindsay
    Cohn, Susan E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (12) : 1129 - 1143
  • [10] Adherence to topical dermatological therapy: lessons from oral drug treatment
    Gupta, G.
    Mallefet, P.
    Kress, D. W.
    Sergeant, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (02) : 221 - 227